|
2009-07-03 |
Impact of Human Recombinant Erithoropoietin (ior EPOCIM) in cancer patients with post Chemo and Radiotherapy induced anemia. |
CIMAB |
Registered |
|
2009-07-03 |
Impact of Recombinant Human Erythropoietin (ior EPO-CIM) in oncology pediatric patients with post chemo and /or radiotherapy. |
CIMAB |
Registered |
|
2009-07-24 |
Impact of the Granulocytes Colony-Stimulating Factor (ior-LeukoCIM) in primary and secondary prophylaxis and post chemotherapy and/or radiotherapy neutropenia in oncohematological pediatric patients. |
CIMAB |
Registered |
|
2010-12-28 |
InCarbacel-II |
CIGB |
Registered |
|
2010-12-24 |
InCCNM -I |
CIGB |
Registered |
|
2009-12-24 |
InCroMiel I |
CIGB |
Registered |
|
2011-07-11 |
INJURE Study |
CIGB |
Registered |
|
2011-05-19 |
InMuMyel I Study |
CIGB |
Registered |
|
2013-03-06 |
Inmunogenicity-PCV-Carriage-Venezuelan High Risk Children |
SAIB |
Registered |
|
09/10/2014 |
Insufflation with CO2 versus room air in colonoscopy |
CNCMA |
Registered |
|
22/08/2013 |
Interferon Combination in basal cell carcinoma (InCarbacel-IV study) |
CIGB |
Registered |
|
2013-02-01 |
Interferon Combination in basal cell carcinoma (InCarbacel-V study) |
CIGB |
Registered |
|
2008-11-14 |
Intraoperative endoscopic retrograde sphincterotomy as a modality of treatment of choledocholithiasis |
CNCMA |
Registered |
|
2013-01-17 |
Intravenous CIGB-128-A in patients with brain tumors (BRATINC Study) |
CIGB |
Registered |
|
2013-02-26 |
ior EPOCIM ® in the management of anemia of the preterm infant.Phase IV. |
CIMAB |
Registered |
|
26/08/2013 |
ior ®EPOCIM as a cardioprotective agent in the surgery of rheumatic valvular disease. |
CIMAB |
Registered outdated |
|
2012-09-17 |
iorEPOCIM-Stroke-Phase I |
CIMAB |
Registered outdated |
|
18/06/2021 |
ior®EPOCIM in post-COVID-19 convalescent patients with cardiovascular, renal and/or respiratory disorders |
CIM |
Registered outdated |
|
23/12/2016 |
Itolizumab (T1h) combined with insulin in patients with Type I Diabetes Mellitus |
CIM |
Registered |
|
08/10/2015 |
Itolizumab for Moderate-to-Severe Psoriasis-phase 3 |
CIM |
Registered |
